Motilal Oswal Alternates has invested USD 72 million in Sensa Core Medical Instrumentation to accelerate product development and expand its global reach in the medical device industry.

Target Company Overview

Motilal Oswal Alternates has made a significant minority investment of USD 72 million in Sensa Core Medical Instrumentation, a company renowned for its innovative medical devices aimed at enhancing healthcare technology in India. Established in Hyderabad in 2006, Sensa Core specializes in the design, development, manufacturing, and distribution of specialized in-vitro diagnostic (IVD) devices. Over the years, it has transformed from a bootstrapped start-up into a market leader in Electrolyte Analysers, with extensive adoption across more than 40,000 hospitals and diagnostic labs within India, as well as export operations in over 78 countries. The company has also emerged as a prominent player in manufacturing Glucometers and Hemoglobin meters, and is currently expanding its product line to include Arterial Blood Gas Analysers.

Sensa Core operates a dedicated manufacturing facility located in Hyderabad’s Export Promotion Industrial Park in Pashamylaram, and is set to open an additional facility in the Medical Device Park in Sultanpur, Hyderabad. This expansion aims to increase production capacity and enhance capabilities for new product development. Under the leadership of Dr. Ravi Kumar Meruva, a technocrat with over 30 years of experience in electrochemistry and medical technology, Sensa Core is poised to accelerate its growth and global presence.

Industry Overview

India's medical device industry represents a rapidly growing sector, projected to reach USD 24 billion by 2024. Despite its potential, the country currently imports over 75% of its medical devices, resulting in an expenditure exceeding USD 8.5 billion ann